This trial is conducted in Europe. The aim of this trial is to investigate the safety,
tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of
NNC 0148-0000-0362 as tablets in healthy volunteers.
The trial consists of two parts. In part 1, single escalating doses of NNC 0148-0000-0362,
placebo or insulin glargine is given. In part 2, subjects will receive single doses of NNC
0148-0000-0362 administered orally or intravenously.